1.ERRATUM: Imaging follow-up strategy after endovascular treatment of intracranial aneurysms: A literature review and guideline recommendations
Yong-Hwan CHO ; Jaehyung CHOI ; Chae-Wook HUH ; Chang Hyeun KIM ; Chul Hoon CHANG ; Soon Chan KWON ; Young Woo KIM ; Seung Hun SHEEN ; Sukh Que PARK ; Jun Kyeung KO ; Sung-kon HA ; Hae Woong JEONG ; Hyen Seung KANG ;
Journal of Cerebrovascular and Endovascular Neurosurgery 2025;27(1):80-80
2.ERRATUM: Imaging follow-up strategy after endovascular treatment of intracranial aneurysms: A literature review and guideline recommendations
Yong-Hwan CHO ; Jaehyung CHOI ; Chae-Wook HUH ; Chang Hyeun KIM ; Chul Hoon CHANG ; Soon Chan KWON ; Young Woo KIM ; Seung Hun SHEEN ; Sukh Que PARK ; Jun Kyeung KO ; Sung-kon HA ; Hae Woong JEONG ; Hyen Seung KANG ;
Journal of Cerebrovascular and Endovascular Neurosurgery 2025;27(1):80-80
3.ERRATUM: Imaging follow-up strategy after endovascular treatment of intracranial aneurysms: A literature review and guideline recommendations
Yong-Hwan CHO ; Jaehyung CHOI ; Chae-Wook HUH ; Chang Hyeun KIM ; Chul Hoon CHANG ; Soon Chan KWON ; Young Woo KIM ; Seung Hun SHEEN ; Sukh Que PARK ; Jun Kyeung KO ; Sung-kon HA ; Hae Woong JEONG ; Hyen Seung KANG ;
Journal of Cerebrovascular and Endovascular Neurosurgery 2025;27(1):80-80
4.Imaging follow-up strategy after endovascular treatment of Intracranial aneurysms: A literature review and guideline recommendations
Yong-Hwan CHO ; Jaehyung CHOI ; Chae-Wook HUH ; Chang Hyeun KIM ; Chul Hoon CHANG ; Soon Chan KWON ; Young Woo KIM ; Seung Hun SHEEN ; Sukh Que PARK ; Jun Kyeung KO ; Sung-kon HA ; Hae Woong JEONG ; Hyen Seung KANG ;
Journal of Cerebrovascular and Endovascular Neurosurgery 2024;26(1):13-22
Objective:
Endovascular coil embolization is the primary treatment modality for intracranial aneurysms. However, its long-term durability remains of concern, with a considerable proportion of cases requiring aneurysm reopening and retreatment. Therefore, establishing optimal follow-up imaging protocols is necessary to ensure a durable occlusion. This study aimed to develop guidelines for follow-up imaging strategies after endovascular treatment of intracranial aneurysms.
Methods:
A committee comprising members of the Korean Neuroendovascular Society and other relevant societies was formed. A literature review and analyses of the major published guidelines were conducted to gather evidence. A panel of 40 experts convened to achieve a consensus on the recommendations using the modified Delphi method.
Results:
The panel members reached the following consensus: 1. Schedule the initial follow-up imaging within 3-6 months of treatment. 2. Noninvasive imaging modalities, such as three-dimensional time-of-flight magnetic resonance angiography (MRA) or contrast-enhanced MRA, are alternatives to digital subtraction angiography (DSA) during the first follow-up. 3. Schedule mid-term follow-up imaging at 1, 2, 4, and 6 years after the initial treatment. 4. If noninvasive imaging reveals unstable changes in the treated aneurysms, DSA should be considered. 5. Consider late-term follow-up imaging every 3–5 years for lifelong monitoring of patients with unstable changes or at high risk of recurrence.
Conclusions
The guidelines aim to provide physicians with the information to make informed decisions and provide patients with high-quality care. However, owing to a lack of specific recommendations and scientific data, these guidelines are based on expert consensus and should be considered in conjunction with individual patient characteristics and circumstances.
5.Silicate Ions Derived from Calcium Silicate Extract Decelerate Ang II-Induced Cardiac Remodeling
Xin LI ; Yanxin ZHANG ; Qishu JIN ; Qiaoyu SONG ; Chen FAN ; Yiren JIAO ; Chen YANG ; Jiang CHANG ; Zhihong DONG ; Yumei QUE
Tissue Engineering and Regenerative Medicine 2023;20(5):671-681
BACKGROUND:
Pathological cardiac hypertrophy is one of the main activators of heart failure. Currently, no drug can completely reverse or inhibit the development of pathological cardiac hypertrophy. To this end, we proposed a silicate ion therapy based on extract derived from calcium silicate (CS) bioceramics for the treatment of angiotensin II (Ang II) induced cardiac hypertrophy.
METHODS:
In this study, the Ang II induced cardiac hypertrophy mouse model was established, and the silicate ion extract was injected to mice intravenously. The cardiac function was evaluated by using a high-resolution Vevo 3100 small animal ultrasound imaging system. Wheat germ Agglutinin, Fluo4-AM staining and immunofluorescent staining was conducted to assess the cardiac hypertrophy, intracellular calcium and angiogenesis of heart tissue, respectively.
RESULTS:
The in vitro results showed that silicate ions could inhibit the cell size of cardiomyocytes, reduce cardiac hypertrophic gene expression, including atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and b-myosin heavy chain (b-MHC), decrease the content of intracellular calcium induced by Ang II. In vivo experiments in mice confirmed that intravenous injection of silicate ions could remarkably inhibit the cardiac hypertrophy and promote the formation of capillaries, further alleviating Ang II-induced cardiac function disorder.
CONCLUSION
This study demonstrated that the released silicate ions from CS possessed potential value as a novel therapeutic strategy of pathological cardiac hypertrophy, which provided a new insight for clinical trials.
6.Central Sarcopenia, Frailty and Comorbidity as Predictor of Surgical Outcome in Elderly Patients with Degenerative Spine Disease
Dong Uk KIM ; Hyung Ki PARK ; Gyeoung Hae LEE ; Jae Chil CHANG ; Hye Ran PARK ; Sukh Que PARK ; Sung Jin CHO
Journal of Korean Neurosurgical Society 2021;64(6):995-1003
Objective:
: People are living longer and the elderly population continues to increase. The incidence of degenerative spinal diseases (DSDs) in the elderly population is quite high. Therefore, we are facing more cases of DSD and offering more surgical solutions in geriatric patients. Understanding the significance and association of frailty and central sarcopenia as risk factors for spinal surgery in elderly patients will be helpful in improving surgical outcomes. We conducted a retrospective cohort analysis of prospectively collected data to assess the impact of preoperative central sarcopenia, frailty, and comorbidity on surgical outcome in elderly patients with DSD.
Methods:
: We conducted a retrospective analysis of patients who underwent elective spinal surgery performed from January 1, 2019 to September 30, 2020 at our hospital. We included patients aged 65 and over who underwent surgery on the thoracic or lumbar spine and were diagnosed as DSD. Central sarcopenia was measured by the 50th percentile of psoas : L4 vertebral index (PLVI) using the cross-sectional area of the psoas muscle. We used the Korean version of the fatigue, resistance, ambulation, illnesses, and loss of weight (K-FRAIL) scale to measure frailty. Comorbidity was confirmed and scored using the Charlson Comorbidity Index (CCI). As a tool for measuring surgical outcome, we used the Clavien-Dindo (CD) classification for postoperative complications and the length of stay (LOS).
Results:
: This study included 85 patients (35 males and 50 females). The mean age was 74.05±6.47 years. Using the K-FRAIL scale, four patients were scored as robust, 44 patients were pre-frail and 37 patients were frail. The mean PLVI was 0.61±0.19. According to the CD classification, 50 patients were classified as grade 1, 19 as grade 2, and four as grade 4. The mean LOS was 12.35±8.17 days. Multivariate stepwise regression analysis showed that postoperative complication was significantly associated with surgical invasiveness and K-FRAIL scale. LOS was significantly associated with surgical invasiveness and CCI. K-FRAIL scale showed a significant correlation with CCI and PLVI.
Conclusion
: The present study demonstrates that frailty, comorbidity, and surgical invasiveness are important risk factors for postoperative complications and LOS in elderly patients with DSD. Preoperative recognition of these factors may be useful for perioperative optimization, risk stratification, and patient counseling.
7.Expert consensus on Tongsaimai Tablets/Capsules in treatment of peripheral vascular diseases in clinical practice.
Ye-Min CAO ; Yu-Zhen WANG ; Xiao-Hua PEI ; Bo-Hua YANG ; Cheng ZHAO ; Yu-Dong FANG ; Hua-Fa QUE ; Yu-Feng JIANG ; Xu-Ying XU ; Cheng-Yong XIA ; Jian-Qiang ZHANG ; Chun-Hong HE ; Li-Ren MA
China Journal of Chinese Materia Medica 2021;46(24):6568-6573
Tongsaimai Tablets/Capsules are composed of Lonicerae Japonicae Flos, Angelicae Sinensis Radix, Achyranthis Bidentatae Radix, Codonopsis Radix, Dendrobii Caulis, Astragali Radix, Scrophulariae Radix, and Glycyrrhizae Radix et Rhizoma, and are effective in promoting blood circulation, removing blood stasis, supplementing Qi, and nourishing Yin. It is widely used in the treatment of peripheral vascular diseases. With 40 years of clinical application, it has accumulated substantial research data and application experience. Its good clinical efficacy and pharmacoeconomic benefits in improving the clinical symptoms of peripheral vascular diseases have been confirmed by relevant research. Meanwhile, this drug has also been recommended by many expert consensus, guidelines, and teaching materials, serving as one of the most commonly used Chinese patent medicines in clinical practice. To further improve the understanding of the drug among clinicians and properly guide its clinical medication, the China Association of Chinese Medicine took the lead and organized experts to jointly formulate this expert consensus. Based on the questionnaire survey of clinicians and the systematic review of research literature on Tongsaimai Tablets/Capsules with clinical problems in the PICO framework, the consensus, combined with expert experience, concludes recommendations or consensus suggestions by GRADE system with the optimal evidence available through the nominal group technique. This consensus defines the indications, usage, dosage, course of treatment, medication time, combined medication, and precautions of Tongsaimai Tablets/Capsules in the treatment of peripheral vascular diseases, and explains the safety of its clinical application. It is recommended for clinicians and pharmacists in the peripheral vascular department(vascular surgery), traditional Chinese medicine surgery(general surgery), and endocrinology department of hospitals at all levels in China.
Capsules
;
Consensus
;
Drugs, Chinese Herbal
;
Humans
;
Medicine, Chinese Traditional
;
Peripheral Vascular Diseases
;
Tablets
8.Semi-quantitative risk assessment of the contamination of Vibrio parahaemolyticus in oysters from Jinshan District, Shanghai
Chen-chen LI ; Dong-fang HAN ; Feng-xia QUE ; Hong-yan WU ; Dan-dan YU ; Yu-long YE
Shanghai Journal of Preventive Medicine 2021;33(3):232-
Objective To investigate the prevalence of
10.Dirofilariasis in Vietnam: A case report and brief review
Que, A.T. ; Nguyen, D.N. ; Do, N.A. ; Le, T.A.
Tropical Biomedicine 2019;36(2):475-481
This report describes a rare case of ophthalmic dirofilariasis in a 68-year-old
woman with red and foreign body sensation in the pterygium on her right eye. Slit lamp
examination demonstrated a long-slender worm moving in her pterygium. The worm was
removed surgically and then identified as Diroflaria repens by sequence analysis of the
small subunit ribosomal RNA (SSU) gene. The situation of dirofilariasis in Vietnam has
been reviewed. Since the first described case in 2010 there have been thirteen cases
reported that suggested the emerging trend of the disease. Most of the documented cases
of human dirofilariasis recorded in Vietnam presented with ocular infections and the
responsible agent was D. repens. With the increase of reported cases of human, much more
attention should be paid on control as well as diagnosis and treatment of dirofilariasis in
Vietnam.


Result Analysis
Print
Save
E-mail